Oscar Health's stock has surged 126% this year, driven by a 47% increase in ACA marketplace enrollment despite overall market declines. The company, now the second-largest insurer on the ACA exchange, has raised its earnings outlook and improved its medical loss ratio, signaling better profitability. Analysts have responded positively, with Barclays raising the price target to $49 and Zacks assigning a Strong Buy rating. This growth and financial strength suggest continued investor confidence in Oscar Health's expansion strategy.
Oscar Health's impressive stock surge is mirrored by strong buying interest on Pluang, where the stock trades at USD 33.02 as of Sep 17, 2026 19:44 WIB. The stock is up 2.10% in the last day, with a market cap of $9.98 billion. Investors on Pluang hold the stock for an average of 14 days, showing confidence in its medium-term potential.
